Capture.Study vs Veeva Vault CDMS: A Faster Start for Smaller Trials
Veeva Vault CDMS is an enterprise EDC built for large pharma programs already standardized on the wider Veeva ecosystem. Most teams comparing it to Capture.Study are looking for something that fits a smaller study and budget, without an enterprise procurement process. Here is an honest look at both.
Who This Comparison Is For
Veeva Vault CDMS and Capture.Study serve very different points on the market. This page is useful if:
You are a small biotech or CRO
- Comparing Veeva against lighter options for a Phase I or II trial
- Want to avoid an enterprise procurement and implementation cycle
- Need public pricing rather than a custom enterprise quote
You already run on the Veeva Vault ecosystem
- Veeva Vault CDMS is likely still the better fit today if your program is already standardized on Vault applications
- This page tells you honestly where that is true
Quick Comparison Table
| Feature | Capture.Study | Veeva Vault CDMS |
|---|---|---|
| Self-serve free sandbox, no sales call to start | Enterprise sales process | |
| Typical time to first build | Under 1 hour | Weeks of implementation |
| AI drafts CRFs from a protocol or description | Not a standard feature | |
| Built for large, multi-thousand-patient Phase III programs | Not the target use case | |
| ePRO, eConsent and randomization in one platform | Separate Vault applications | |
| Public, self-serve pricing | Custom enterprise pricing | |
| 21 CFR Part 11-aligned controls | ||
| Track record in large pharma submissions | Newer platform |
We built this table from each vendor's own public positioning. If anything here is out of date, let us know.
Getting Started
Veeva Vault CDMS is sold through an enterprise sales process, typically alongside other Vault applications, with implementation measured in weeks to months. Capture.Study is self-serve: you can build and test your full study in a free sandbox today, with no credit card and no sales call, and only pay once you go live.
If your study is small to mid-size and speed to first patient matters more than a multi-application Vault rollout, that gap usually decides it.
Study Build
Veeva Vault CDMS study builds are commonly handled by Vault-certified specialists or CRO partners, reflecting the platform's enterprise configuration model. Capture.Study puts AI-assisted drafting and a visual builder directly in the hands of the study team, so a smaller protocol does not need a dedicated build specialist.
Scale
Veeva Vault CDMS is built for large, multinational pharma programs already invested in the wider Vault ecosystem (eTMF, RIM, safety and more). Capture.Study targets a different point on the scale: early-phase, academic and small-to-mid-size trials that do not need a multi-application enterprise platform and do not want to pay for one. Neither platform is trying to be the other.
Compliance
Veeva has an extensive track record supporting FDA and global regulatory submissions across large pharma programs. Capture.Study provides 21 CFR Part 11-aligned controls today, a field-level audit trail that cannot be edited from the app, OTP-verified electronic signatures with countersignature, and role-based access, with documentation to support your own validation on Enterprise plans. If your program specifically needs Veeva's submission history and multi-application scale, that is a real, current advantage on their side.
Pricing
Veeva does not publish pricing. Public market research estimates Vault CDMS licensing at roughly $500 to $2,400 per user per year, which can total $513,000 to $2.2 million in year one for a 50 to 100-user biotech team once implementation is included. Treat that as a market estimate, not a quote. Capture.Study includes a free sandbox for every study, with paid plans that scale with study size, visible without a sales conversation.
When Veeva Vault CDMS Is Still the Right Choice
Large, multinational Phase III programs
If you are running a multi-thousand-patient global trial with a dedicated study-build team, Veeva's scale and track record are hard to match.
You are already standardized on Veeva Vault
If your organization already runs eTMF, RIM or safety on Vault, adding Vault CDMS keeps everything in one ecosystem.
When Capture.Study Is the Better Choice
You want to start without an enterprise sales cycle
Build and test your entire study in the free sandbox today. No procurement process required to see if it fits.
Your study does not need Vault's multi-application scale
Phase I/II, academic and small-to-mid-size trials get the compliance controls they need without the overhead of a multi-application enterprise platform.
You want your own team to build and amend forms
AI-assisted drafting and a visual builder mean your study team can build and adjust CRFs without a Vault-certified specialist.
Frequently Asked Questions
Is Capture.Study a Veeva Vault CDMS alternative?
For small-to-mid-size and early-phase trials, yes. For large, multinational Phase III programs already standardized on Veeva Vault, Vault CDMS remains built for a scale Capture.Study does not target today.
Why is Veeva so much more expensive than Capture.Study?
Veeva prices Vault CDMS for large, complex, multi-application programs with dedicated implementation and support. Capture.Study is built and priced for smaller studies that do not need that scale.
Can I try Capture.Study before deciding?
Yes. The free sandbox includes every feature with sample data, no credit card and no time limit, so you can test it against your own protocol.
Is Capture.Study 21 CFR Part 11-aligned like Veeva?
Yes. Capture.Study provides a field-level audit trail, OTP-verified electronic signatures with countersignature, and role-based access control, with documentation to support sponsor validation on Enterprise plans.
See If Capture.Study Fits Your Study
Free sandbox with no time limit. Build your study and test everything before paying a dollar.
No credit card required. No sales calls.